Navigation Links
Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:4/14/2008

REDWOOD CITY, Calif., April 14 /PRNewswire/ -- Codexis, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. Copies of the Codexis registration statement on Form S-1 can be accessed through the SEC's website at edgar.sec.gov. The number of shares being offered and the price range for the offering have not yet been determined. The shares of common stock to be sold in this offering are proposed to be sold by Codexis, Inc.

Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. will be acting as joint book-running managers, with Piper Jaffray & Co., RBC Capital Markets Corporation and Thomas Weisel Partners LLC acting as co-managers for the offering. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from the prospectus department of Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, via telephone at 800-221-1037; or from the prospectus department of Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad Street, New York, New York 10004, via fax at 212-902-9316.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall neither constitute an offer to sell nor a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Codexis

Codexis is a leading developer of proprietary biocatalysts that the company believes have the potential to revolutionize chemistry-based manufacturing processes across a variety of industries. The company has used its technology platform to enable biocatalyst-based commercial-scale drug manufacturing processes and delivered biocatalysts and drug products to some of the world's leading pharmaceutical companies. Codexis has a funded collaboration in the biofuels market, and the company is pursuing funded collaborations in several other bioindustrial markets, including carbon management, water treatment and chemicals.

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Justin Jackson, Burns McClellan, jjackson@burnsmc.com, 212-213-0006.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Immunosyn Corporation Announces 2007 Results, Files 10KSB
2. Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
3. Watson Files FDA Application for Generic LYBREL(R)
4. CryoCor Files Patent Infringement Lawsuits Against CryoCath
5. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
6. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Roche Files IND for Second Genmab Antibody
9. Sequoia Pharmaceuticals Files Second IND for 2007
10. CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007
11. Aida Files 10Q
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
Breaking Biology Technology:
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
Breaking Biology News(10 mins):